M T Abreu

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi Combination therapy with infliximab and immunomodulators: is the glass half empty?
    Amar R Deshpande
    Gastroenterology 134:2161-3. 2008
  2. ncbi Modulation of barrier function during Fas-mediated apoptosis in human intestinal epithelial cells
    M T Abreu
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 119:1524-36. 2000
  3. ncbi TLR signaling at the intestinal epithelial interface
    Maria T Abreu
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Endotoxin Res 9:322-30. 2003
  4. ncbi The pathogenesis of inflammatory bowel disease: translational implications for clinicians
    Maria T Abreu
    Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8631 West 3rd Street, Suite 245E, Los Angeles, CA 90048, USA
    Curr Gastroenterol Rep 4:481-9. 2002
  5. ncbi Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
    Maria T Abreu
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 123:679-88. 2002
  6. ncbi Controversies in IBD. Serologic tests are helpful in managing inflammatory bowel disease
    Maria T Abreu
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 8:224-6; discussion 223, 230-1. 2002
  7. ncbi TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells
    Maria T Abreu
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Biol Chem 277:20431-7. 2002
  8. pmc Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density
    M T Abreu
    Division of Gastroenterology, Inflammatory Bowel Disease Center, Steven Spielberg Pediatric Research Center, Burns and Allen Research Institute, Los Angeles, CA 90048, USA
    Gut 53:1129-36. 2004
  9. ncbi Phosphatidylinositol 3-kinase-dependent pathways oppose Fas-induced apoptosis and limit chloride secretion in human intestinal epithelial cells. Implications for inflammatory diarrheal states
    M T Abreu
    Inflammatory Bowel Disease Center and Burns and Allen Research Institute, Cedars Sinai Medical Center, 8631 West 3rd Street, Suite 245E, Los Angeles, CA 90048, USA
    J Biol Chem 276:47563-74. 2001
  10. ncbi Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide
    M T Abreu
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, 8631 West 3rd Street, Los Angeles, CA 90048, USA
    J Immunol 167:1609-16. 2001

Collaborators

Detail Information

Publications56

  1. ncbi Combination therapy with infliximab and immunomodulators: is the glass half empty?
    Amar R Deshpande
    Gastroenterology 134:2161-3. 2008
  2. ncbi Modulation of barrier function during Fas-mediated apoptosis in human intestinal epithelial cells
    M T Abreu
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 119:1524-36. 2000
    ..We hypothesized that increased, immune-mediated apoptosis during inflammation might result in barrier dysfunction of the epithelium...
  3. ncbi TLR signaling at the intestinal epithelial interface
    Maria T Abreu
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Endotoxin Res 9:322-30. 2003
    ..The Th1 cytokine IFN-gamma up-regulates expression of MD-2 in a STAT-dependent fashion. The results of our studies have important implications for understanding human inflammatory bowel diseases...
  4. ncbi The pathogenesis of inflammatory bowel disease: translational implications for clinicians
    Maria T Abreu
    Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8631 West 3rd Street, Suite 245E, Los Angeles, CA 90048, USA
    Curr Gastroenterol Rep 4:481-9. 2002
    ..The next stage of research will take advantage of such molecular biologic techniques to identify new pathogenetic mechanisms and targets for therapy tailored to individual patients...
  5. ncbi Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
    Maria T Abreu
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 123:679-88. 2002
    ..NOD2 gene mutations in CD have been described recently and may alter innate immune responses. We hypothesized that NOD2 mutations may be associated with distinct phenotypic expressions of CD...
  6. ncbi Controversies in IBD. Serologic tests are helpful in managing inflammatory bowel disease
    Maria T Abreu
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 8:224-6; discussion 223, 230-1. 2002
  7. ncbi TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells
    Maria T Abreu
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Biol Chem 277:20431-7. 2002
    ..Th1 cytokines may initiate or perpetuate intestinal inflammation by altering toll-like receptor expression and bacterial reactivity...
  8. pmc Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density
    M T Abreu
    Division of Gastroenterology, Inflammatory Bowel Disease Center, Steven Spielberg Pediatric Research Center, Burns and Allen Research Institute, Los Angeles, CA 90048, USA
    Gut 53:1129-36. 2004
    ..We further hypothesised that this was secondary to increased synthesis of 1,25(OH)(2)D by inflammatory cells in the intestine. The aim of this study was to examine the relationship between 1,25(OH)(2)D levels and BMD in patients with CD...
  9. ncbi Phosphatidylinositol 3-kinase-dependent pathways oppose Fas-induced apoptosis and limit chloride secretion in human intestinal epithelial cells. Implications for inflammatory diarrheal states
    M T Abreu
    Inflammatory Bowel Disease Center and Burns and Allen Research Institute, Cedars Sinai Medical Center, 8631 West 3rd Street, Suite 245E, Los Angeles, CA 90048, USA
    J Biol Chem 276:47563-74. 2001
    ..These findings suggest that agonists of PI3-kinase such as growth factors may have a dual effect on intestinal inflammation by protecting epithelial cells against immune-mediated apoptosis and limiting chloride secretory diarrhea...
  10. ncbi Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide
    M T Abreu
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, 8631 West 3rd Street, Los Angeles, CA 90048, USA
    J Immunol 167:1609-16. 2001
    ..We conclude that IEC limit dysregulated LPS signaling by down-regulating expression of MD-2 and TLR4. The remainder of the intracellular LPS signaling pathway is functionally intact...
  11. ncbi An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy
    M C Dubinsky
    Department of Medicine, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 7:181-9. 2001
    ..This pilot study evaluated the safety, tolerance, and efficacy of 6-TG in the subgroup of Crohn's disease (CD) patients failing to attain adequate disease control with traditional 6-MP/AZA therapy...
  12. ncbi Outcome of cytomegalovirus infections in patients with inflammatory bowel disease
    K A Papadakis
    Division of Gastroenterology, Cedars-Sinai Inflammatory Bowel Disease Center, Los Angeles, California 90048, USA
    Am J Gastroenterol 96:2137-42. 2001
    ..Expedient evaluation, prompt treatment intervention with ganciclovir, and withdrawal of immunosuppressive treatment may avoid complications and mortality. This regimen leads to improvement of the underlying IBD in most patients...
  13. pmc Role of Toll-like receptors in gastrointestinal malignancies
    M Fukata
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Oncogene 27:234-43. 2008
    ..Studying the link between innate immune signaling and gastrointestinal malignancies offers the possibility to identify novel ways to both prevent and treat gastrointestinal cancer...
  14. ncbi TLR4 signalling in the intestine in health and disease
    M Fukata
    Inflammatory Bowel Disease Center, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Biochem Soc Trans 35:1473-8. 2007
    ..The pathogenesis of IBD, ulcerative colitis and Crohn's disease may be due to increased TLR or decreased TLR signalling respectively. Finally, we discuss the possible role of TLR signalling in colitis-associated neoplasia...
  15. ncbi Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease
    Jacob Spivak
    Division of Colon and Rectal Surgery, Department of Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Inflamm Bowel Dis 12:1122-30. 2006
    ..This study examines the association between clinical features and seroreactivity to these microbial and auto-antigens in predicting a clinical response to fecal diversion...
  16. pmc Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine
    Masayuki Fukata
    Inflammatory Bowel Disease Center, Division of Gastroenterology, New York, New York, USA
    Gastroenterology 131:862-77. 2006
    ..We wished to test the hypothesis that cyclooxygenase 2 (Cox-2)-derived prostaglandin E2 (PGE2) is important in TLR4-related mucosal repair...
  17. ncbi Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease
    Maria T Abreu
    Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Mount Sinai School of Medicine, New York, NY, USA
    J Clin Gastroenterol 40:55-63. 2006
    ..The aim of this study was to assess the ability of treatment with the TNF-alpha antagonist infliximab to increase bone formation as measured by surrogate markers of bone turnover in patients with active CD...
  18. ncbi Nod2 in normal and abnormal intestinal immune function
    Maria T Abreu
    Mount Sinai School of Medicine, New York, New York 10029, USA
    Gastroenterology 129:1302-4. 2005
  19. ncbi NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives
    Shane M Devlin
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 132:576-86. 2007
    ..The aim of our study was to determine if defects in innate immunity are similarly associated with increased adaptive immune responses to microbial antigens in Crohn's disease patients...
  20. ncbi Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations
    Konstantinos A Papadakis
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, California, USA
    Inflamm Bowel Dis 13:524-30. 2007
    ..We examined the association between anti-CBir1 and clinical phenotypes and NOD2 variants in a large cohort of adult CD patients...
  21. ncbi Translational research in inflammatory bowel disease
    Maria T Abreu
    Inflammatory Bowel Disease Center, Mount Sinai School of Medicine, 1 East 100th Street, Box 1069, New York, NY 10029, USA
    Mt Sinai J Med 73:1067-73. 2006
    ..This article presents an update on these key developments and emphasizes the translational aspects of research that are directly related to patient care...
  22. ncbi Selective leukocyte apheresis for the treatment of inflammatory bowel disease
    Maria T Abreu
    Inflammatory Bowel Disease Center, New York, NY, USA
    J Clin Gastroenterol 41:874-88. 2007
    ..Despite these findings, large controlled trials of selective leukocyte apheresis in the treatment of IBD are needed to determine the true efficacy of this approach...
  23. pmc Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria
    Limin Shang
    Immunology Institute, Mount Sinai School of Medicine, New York, New York, USA
    Gastroenterology 135:529-38. 2008
    ..We hypothesized that TLR signaling at the level of the intestinal epithelium is critical for mucosal immune responses...
  24. ncbi TLR signaling in the gut in health and disease
    Maria T Abreu
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Immunol 174:4453-60. 2005
    ..A better understanding of the delicate regulation of TLR and Nod molecules in the gut may lead to improved treatment for enteric infections and idiopathic inflammatory bowel diseases...
  25. ncbi Innate immunity and toll-like receptors: clinical implications of basic science research
    Maria T Abreu
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Steven Spielberg Pediatric Research Center, Los Angeles, CA 90048, USA
    J Pediatr 144:421-9. 2004
    ..The focus of this article is to describe the role of TLRs in the innate immune response in health and disease...
  26. ncbi Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease
    Stephen A Geller
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Surg Pathol 28:1204-11. 2004
    ..6-TG-related hepatotoxicity, including liver biochemistry value elevations, sinusoidal collagen deposition on electron microscopy, and veno-occlusive disease, have been described related to its use as therapy for neoplastic disease...
  27. ncbi Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine
    Marla C Dubinsky
    Department of Medicine, Division of Gastroenterology, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Am J Gastroenterol 98:1058-63. 2003
    ..The aim of this study was to determine if hypersensitivity reactions to 6-MP/AZA reoccur with 6-TG therapy...
  28. ncbi Is genetic testing in IBD ready for prime time?
    Maria T Abreu
    Am J Gastroenterol 99:316-8. 2004
  29. ncbi Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut
    Gil Melmed
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Immunol 170:1406-15. 2003
    ..The relative absence of TLR2 protein expression by IEC and high level of Tollip expression may be important in preventing chronic proinflammatory cytokine secretion in response to commensal Gram-positive bacteria in the gut...
  30. ncbi Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells
    Puja Vora
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Immunol 173:5398-405. 2004
    ..This mechanism may protect the intestinal epithelium from pathogen invasion and from potential invaders among the commensal flora...
  31. ncbi New insights into the pathogenesis of inflammatory bowel disease
    Gil Y Melmed
    Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Mount Sinai School of Medicine, 1190 Fifth Avenue, New York, NY 10029, USA
    Curr Gastroenterol Rep 6:474-81. 2004
    ..In this review we summarize these key developments in the pathophysiology of inflammatory bowel disease and attempt to ascribe clinical relevance where applicable...
  32. pmc The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease
    Masayuki Fukata
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Immunol 180:1886-94. 2008
    ..Absence of MyD88 in CD4(+)CD45Rb(high) cells results in defective T cell function, especially Th17 differentiation. These results suggest a role for TLR signaling by T cells in the development of inflammatory bowel disease...
  33. ncbi Crohn's disease in patients who fail infliximab therapy: what does the future hold?
    Maria T Abreu
    Inflammatory Bowel Disease Center, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Rev Gastroenterol Disord 7:S20-6. 2007
    ..This article looks at recent studies using these newer TNF inhibitors in patients in whom infliximab treatment has failed as well as in those who have never received infliximab...
  34. ncbi 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
    Marla C Dubinsky
    Division of Gastroenterology and Genetics, Department of Medicine and Pediatrics, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Gastroenterology 122:904-15. 2002
    ..The objectives of this study were to determine whether dose escalation optimizes both 6-TGN levels and efficacy in patients failing therapy because of subtherapeutic 6-TGN levels and its effect on TPMT...
  35. ncbi Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients
    Omid A Shaye
    Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Am J Gastroenterol 102:2488-94. 2007
    ..The aim of this study was to assess the prevalence of 6-MP/AZA hepatotoxicity and its correlation with serum 6-MMPR levels in adult IBD patients...
  36. ncbi Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients
    Inés D Pousa
    Department of Hepato Gastroenterology and Ciberehd University Hospital of La Princesa, Universidad Autonoma de Madrid, Spain
    Inflamm Bowel Dis 14:61-7. 2008
    ....
  37. ncbi Analysis of soluble angiogenic factors in Crohn's disease: a preliminary study
    Inés Dueñas Pousa
    Department of Gastroenterology and Hepatology, Hospital of La Princesa, Autonomous University of Madrid, Spain
    Gastroenterol Hepatol 30:518-24. 2007
    ..Soluble angiogenic factors could be altered in patients with Crohns disease (CD), since inflammation and angiogenesis may play a critical pathogenic role...
  38. pmc Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors
    Masayuki Fukata
    Inflammatory Bowel Disease Center, Mount Sinai School of Medicine, New York, New York, USA
    Gastroenterology 133:1869-81. 2007
    ..The molecular mechanisms linking inflammation and colon carcinogenesis are incompletely understood. We tested the hypothesis that Toll-like receptor 4 (TLR4) is involved in tumorigenesis in the setting of chronic inflammation...
  39. ncbi Gut microbes in Crohn's disease: getting to know you better?
    Seamus J Murphy
    Am J Gastroenterol 103:397-8. 2008
    ..This additional marker may complement existing disease markers. Future studies should address whether these antibodies can help categorize patients with indeterminate colitis or predict severity of CD...
  40. ncbi Defining subtypes of Crohn's disease patients: the ground work for translational research in inflammatory bowel disease
    Maria T Abreu
    J Clin Gastroenterol 36:3-4. 2003
  41. ncbi How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice
    Jason S Yip
    Mount Sinai School of Medicine, New York, NY, USA
    Inflamm Bowel Dis 14:514-8. 2008
    ..5 mg/kg/day and 6-MP at 1.5 mg/kg/day. Escalation of dosing is recommended within 2 weeks of initiating therapy. The aim was to determine the prescribing practices of community practice gastroenterologists with respect to 6-MP/AZA dosing...
  42. ncbi 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients
    Marla C Dubinsky
    Pediatric Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8635 West Third Street, Suite 1165W, Los Angeles, California 90048, USA
    Gastroenterology 125:298-303. 2003
    ..The aim of this study was to describe the association between 6-TG and NRH in IBD...
  43. ncbi Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab
    Konstantinos A Papadakis
    Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, 8631 W Third Street, Suite 430E, Los Angeles, CA 90048, USA
    Am J Gastroenterol 100:75-9. 2005
    ..The aim of our study was to examine the safety and efficacy of adalimumab (D2E7), a fully humanized anti-TNF-alpha Ab, in CD patients who had experienced an attenuated response to infliximab...
  44. ncbi Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease
    Steven J Brown
    The Mount Sinai School of Medicine, Division of Gastroenterology, 1 Gustave L Levy Place, New York, NY 10029, USA
    Curr Opin Drug Discov Devel 8:160-8. 2005
    ..We will also address factors that predict response to therapy such as concurrent immunomodulators, high C-reactive protein expression, and polymorphisms in the Fcgamma receptor...
  45. ncbi Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis
    Masayuki Fukata
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Mount Sinai School of Medicine, 1425 Madison Ave, 11 23D, Box 1069, New York, New York 10029, USA
    Am J Physiol Gastrointest Liver Physiol 288:G1055-65. 2005
    ..A defective innate immune response may result in diminished bacterial clearance and ultimately dysregulated response to normal flora...
  46. ncbi Defects in mucosal immunity leading to Crohn's disease
    Gena M Cobrin
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Immunol Rev 206:277-95. 2005
    ..One may consider a model in which defective innate immune clearance of pathogens or commensal bacteria in CD leads to an inappropriate adaptive immune response to the commensal flora...
  47. ncbi Design issues and outcomes in IBD clinical trials
    Bruce E Sands
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Inflamm Bowel Dis 11:S22-8. 2005
    ..Careful subject selection, standardization of disease activity indices, and precise outcome measurement are the keys to continued improvement of the inflammatory bowel disease research process...
  48. ncbi Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease
    Maria T Abreu
    Center for Inflammatory Bowel Disease, Mount Sinai School of Medicine, New York, NY 10029, USA
    Nat Clin Pract Gastroenterol Hepatol 2:210-1. 2005
  49. ncbi The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease
    Robin Matuk
    Department of Medicine, Division of Gastroenterology, Cedars Sinai Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 10:352-6. 2004
    ..Treatment with COX-2 inhibitors is associated with a high incidence of exacerbation of the underlying IBD and GI-related complications...
  50. ncbi Ulcerative colitis therapy: importance of delivery mechanisms
    Jeremy Rochester
    Inflammatory Bowel Disease Center, Department of Gastroenterology, Mount Sinai School of Medicine, New York, NY, USA
    Rev Gastroenterol Disord 5:215-22. 2005
    ..For a given patient, however, it may be necessary to experiment with more than one preparation if an initial trial results in a suboptimal response...
  51. ncbi American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease
    Gary R Lichtenstein
    Hospital of the University of Pennsylvania University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA
    Gastroenterology 130:935-9. 2006
  52. ncbi American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease
    Gary R Lichtenstein
    Hospital of the University of Pennsylvania University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA
    Gastroenterology 130:940-87. 2006
  53. ncbi Use of capsule endoscopy for established Crohn's disease
    Peter Legnani
    Department of Medicine, Mount Sinai School of Medicine, One Gustav L Levy Place, Box 1118, New York, NY 10029, USA
    Gastrointest Endosc Clin N Am 16:299-306. 2006
    ..At this time, use of capsule endoscopy as a tool for the evaluation of mucosal healing or for prognostication of post-operative recurrence remains investigational...
  54. ncbi A pilot study of adalimumab in infliximab-allergic patients
    Adrienne Youdim
    Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 10:333-8. 2004
    ..Based on these preliminary data, adalimumab may be a safe and effective substitute for infliximab-allergic patients. Individuals who have been exposed to human antibodies may be sensitized to other human antibodies such as adalimumab...
  55. ncbi Advances in the pathogenesis of inflammatory bowel disease
    Yuki Young
    Inflammatory Bowel Disease Center, Mount Sinai School of Medicine, 1425 Madison Avenue, 11 23, New York, NY 10029, USA
    Curr Gastroenterol Rep 8:470-7. 2006
    ..This review focuses on developments likely to culminate in advances in patient care...
  56. doi Harnessing the power of bacteria to protect the gut
    Maria T Abreu
    N Engl J Med 359:756-9. 2008